DIGITAL THERAPEUTICS
FOR DEMENTIA

Brain+, is a pioneer in the development of Digital Therapeutics for dementia and Alzheimer’s disease. The clinical target is to counteract cognitive decline, the main symptom of dementia.
Brain+ products digitally deliver Cognitive Stimulation Therapy (CST), the leading non-pharmacological dementia therapy.
CST is recommended to be ‘implemented globally’ in the World Alzheimer’s report 2022.

New research report values Brain+.
DKK 4.1 per share in the base case.
DKK 6.4 in the bull case.

DIGITAL THERAPEUTICS
FOR DEMENTIA

Brain+, is a pioneer in the development of Digital Therapeutics for dementia and Alzheimer’s disease. The clinical target is to counteract cognitive decline, the main symptom of dementia.
Brain+ products digitally deliver Cognitive Stimulation Therapy (CST), the leading non-pharmacological dementia therapy.
CST is recommended to be ‘implemented globally’ in the World Alzheimer’s report 2022.

New research report values Brain+.
DKK 4.1 per share in the base case.
DKK 6.4 in the bull case.

STAY INFORMED

Be the first to receive company updates, press releases and news.

MEET BRAIN+

WHY INVEST IN BRAIN+

The mission of Brain+ is to make effective dementia treatments available to everyone, as digital therapeutics. Dementia is a massive unmet clinical need, with over 57 people diagnosed, a number projected to exceed 150 million by 2050. There is currently no cure to dementia. Instead, there are a few treatments that can help to reduce or alleviate symptoms temporarily.
Digital therapeutics (DTx) can deliver safe, effective evidence-based therapies, and Brain+ has worked for years with world-leading experts to develop its DTx dementia products. Following successful progress in an ongoing partnership with RoX Health, a subsidiary of the global pharma company Roche, Brain+ has been able to accelerate the path to commercial launch by roughly two years.
The first product, CST-Therapist Companion, will be launched during Q4 2022 in Denmark, followed by the German market in Q2 2023. In August 2022, Brain+ initiated a new collaboration with the German medical distributor Coopmed, who will support Brain+ with commercial expertise and distribution. In addition to commercializing, Brain+, has two additional technologies in its pipeline; Computerized Cognitive Training for Mild Cognitive Impairment, and a memory test co-developed with Oxford University, for early detection and monitoring of cognitive decline in Alzheimer’s disease.
These technologies, combined with a broad clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position for DTx for dementia
Kim
Have questions?

Fill out this form
and get contacted by:

Kim Baden-Kristensen
CEO & Co-founder

INVESTOR EVENTS

2022

26 August

Dansk Aktionærforening

Interview with Kim Baden-Kristensen, CEO about dementia product launch in Q4

29 August

Økonomisk Ugebrev

Life Science Investor Conference

31 August

Finwire

Hemma Hos

12 September

Aktiespararna

Aktiedagen Stockholm

14 September

BioStock

Investor Showcase Stockholm

4 October

Fill or Kill

Podcast

4 October

Dansk Aktionærforening

Interview

14 October

ProInvestor

Interview

19 September

Finwire

Sitdown interview

2021

20 December 16:00

DANSK AKTIONÆRFORENING EVENT

Q&A session with Dansk Aktionærforening, talking about the IPO and news of first large-pharma partnership deal.

23 September 16:00

DANSK AKTIONÆRFORENING EVENT

Mikael Bak hosts Brain+ for a company presentation and subsequent session for investors to ask questions.

22 September 16:00

Nordnet Q&A

A chance for investors to ask questions live to Brain+

17 September

Nordnet interview:

A glimpse into Brain+, speaking on the strategy and goals.

16 September

Finwire interview:

Hear from Kim Baden-Kristensen, CEO & Co-Founder, on Brain+ and the plans after the IPO

16 September

ProInvestor interview:

Helge Larsen goes in-depth with Brain+, to discuss Digital Medicine, and how Brain+ will make a difference.

OlderMan-Phone-shutterstock_1877563882-1920x1080

DIGITAL MEDICINE – A GLOBAL HEALTH TREND

The digital medicine trend is the next big thing at the frontier of digitalisation and has already proven a powerful way of dealing with several important diseases, where traditional, chemical medicines have failed. Software-based treatments/therapies have become FDA-approved and several large pharma companies have joined the game. With a current compounded annual growth rate of 23,1% the market size for digital medicine is projected to hit 19,1 billion USD by 2028.

Hands-shutterstock_1702101469-1920x1080

TREATING DEMENTIA AND ALZHEIMER’S
WITH DIGITAL MEDICINE

Dementia and Alzheimer’s are both conditions, where digital medicine has proven to have a significant impact. And with dementia on the rise globally with 50 million people currently diagnosed (a number which is expected to more than triple to 152 million people by 2050), this presents a global addressable market for digital dementia treatments of approximately 2 to 5 billion USD in 10 to 15 years from today.

Hands-shutterstock_1702101469-1920x1080
Stock-Phone-shutterstock_1745613248-1920x1080

FURTHER ANCHORING BRAIN+ AS A MARKET LEADER

The IPO will fund further product development and advancing towards the phase 3 clinical trials needed for regulatory approval in order to attract major pharma companies for strategic partnerships, as Brain+ aims to establish themselves as global market leaders by 2031, with revenue projections in several hundred millions of USD.